ChemoCentryx Jumped by 348%. Is It a Buy?
Shares of ChemoCentryx (NASDAQ: CCXI) have shot up significantly after the company announced positive results for a trial focusing on its leading drug candidate. With investors impressed by this piece of news and Wall Street analysts doubling down on their already optimistic ratings for the company, is this the right time to buy into the stock?
Let's take a deeper look at the trial data in question, the rest of ChemoCentryx's pipeline, and whether investors should buy the biotech stock now or wait for prices to possibly settle down?
Image source: Getty Images.
Source Fool.com
